AstraZeneca Says Forxiga's Cardiovascular Outcomes Benefit Is Approved in China
October 28 2020 - 3:44AM
Dow Jones News
By Matteo Castia
AstraZeneca PLC said Wednesday that the cardiovascular outcomes
benefit of its Forxiga drug to treat type 2 diabetes in adults has
been approved in China by the National Medical Products
Administration.
The pharmaceutical group said the administration has updated
Forxiga's label to include data from the Declare-Time 58 phase 3
trial, which demonstrated Forxiga's effectiveness in reducing the
composite endpoint of hospitalization for heart failure or
cardiovascular death.
Declare-Time 58 is a phase 3 trial designed to evaluate
Forxiga's effects compared with placebo on cardiovascular outcomes
in adults with type 2 diabetes.
Write to Matteo Castia at matteo.castia@dowjones.com
(END) Dow Jones Newswires
October 28, 2020 03:29 ET (07:29 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024
